Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad285 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Daniel Podzamczer und 27 weiteren Autor:innen. Beteiligte Einrichtung: FLScience, Fight Infections Foundation, Badalona, Spain. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Gilead Sciences, Spanish AIDS Research Network, Fight Infections Foundation.
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and safety of the two-pill regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching strategy in heavily treatment-experienced people living with HIV (PLWH).
Methods
Multicentre, prospective, single-arm pilot clinical trial. Participants were virologically suppressed adults receiving a stable antiretroviral regimen of at least three pills from at least three drug families due to previous virological failures and/or toxicities with no documented resistance to integrase strand transfer inhibitors or darunavir (≥15 points, Stanford). Clinical and laboratory assessments were performed at 0, 4, 12, 24, 36 and 48 weeks. HIV-1 proviral DNA was amplified and sequenced by Illumina at baseline. Plasma bictegravir concentrations were determined in 22 patients using UHPLC-MS/MS. The primary study endpoint was viral load (VL)< 50 copies/mL at Week 48 (ITT).
Results
We enrolled 63 participants (92% men) with median baseline CD4 count of 515 cells/mm3 (IQR: 334.5–734.5), 24 years on ART (IQR: 15.9–27.8). The median number of pills was 4 (range: 3–10). At baseline, proviral DNA was amplified in 39 participants: 33/39 had resistance mutations. Three participants discontinued owing to toxicity. At 48 weeks, 95% had VL < 50 copies/mL by ITT and 100% by PP analysis. A modest increase was observed in the bictegravir plasma concentration, and a significant decrease in estimated glomerular filtration rate was observed only at Week 4, probably related to interaction with renal transporters.
Conclusions
Our data suggest that BIC/FTC/TAF + darunavir/cobicistat is an effective, well-tolerated regimen that may improve convenience and, potentially, long-term success in stable heavily pre-treated PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- FLScience, Fight Infections Foundation, Badalona, Spain.
- Infectious Diseases Department, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet del Llobregat, Hospital Universitario de Bellvitge, Spain.
- Infectious Diseases Department, Hospital universitario de Canarias, San Cristóbal de la Laguna, Spain.
- Infectious Diseases Department, Hospital del Mar, Barcelona, Spain.
- Infectious Diseases Department, Hospital Universitario general de Elche, Elche, Spain.
- Infectious Diseases Department, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Hospital General Universitario Gregorio M…
ORCID-Profile: Arkaitz Imaz, Mar Masiá, Jesús Troya, Juan Macias
Förderung
- Gilead Sciences
- Spanish AIDS Research Network
- Fight Infections Foundation
Zitieren
APA
Podzamczer, D., Imaz, A., Lopez-Lirola, A., Knobel, H., Masiá, M., Fanciulli, C., Hernández, C., Lagarde, M., Gutierrez, A., Curran, A., Morano, L., Montero-Alonso, M., Troya, J., Rigo, R., Casadellà, M., Navarro-Alcaraz, A., Ardila, F., Parera, M., Bernal, E., …, & Rivero, A. (2023). Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad285
Vancouver
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad285
BibTeX
@article{Podzamczer2023,
author = {Podzamczer, Daniel and Imaz, Arkaitz and Lopez-Lirola, Ana and Knobel, Hernando and Masiá, Mar and Fanciulli, Chiara and Hernández, Cristina and Lagarde, María and Gutierrez, Angela and Curran, Adrià and Morano, Luis and Montero-Alonso, Marta and Troya, Jesús and Rigo, Raúl and Casadellà, María and Navarro-Alcaraz, Antonio and Ardila, Fernando and Parera, Mariona and Bernal, Enrique and Echeverria, Patricia and Estrada, Vicente and Hidalgo-Tenorio, Carmen and Macias, Juan and Prieto, Paula and Portilla, Joaquín and Valencia, Eulalia and Vivancos, María Jesús and Rivero, Antonio},
title = {Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad285}
}
EUVIMED